Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline
Autore:
Rush, AJ; Trivedi, MH; Carmody, TJ; Donahue, RMJ; Houser, TL; Bolden-Watson, C; Batey, SR; Ascher, JA; Metz, A;
Indirizzi:
Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA Univ Texas Dallas TX USA 75390 d Ctr, Dept Psychiat, Dallas, TX 75390 USA Univ Texas, SW Med Ctr, Acad Comp Serv, Dallas, TX 75390 USA Univ Texas Dallas TX USA 75390 Ctr, Acad Comp Serv, Dallas, TX 75390 USA Glaxo Wellcome Inc, Div US Med Affairs, Res Triangle Pk, NC 27709 USA Glaxo Wellcome Inc Res Triangle Pk NC USA 27709 Triangle Pk, NC 27709 USA Glaxo Wellcome Inc, Clin Dev, Res Triangle Pk, NC 27709 USA Glaxo WellcomeInc Res Triangle Pk NC USA 27709 Triangle Pk, NC 27709 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 1, volume: 25, anno: 2001,
pagine: 131 - 138
SICI:
0893-133X(200107)25:1<131:RIRTBA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; ANTIDEPRESSANT EFFICACY; OUTPATIENTS; FLUOXETINE; PLACEBO; IMIPRAMINE; SAFETY;
Keywords:
major depressive disorder; bupropion SR; sertraline; anxiolysis; pretreatment anxiety; retrospective analysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Rush, AJ Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA Univ Texas 5323 Harry Hines Blvd Dallas TX USA 75390 TX 75390 USA
Citazione:
A.J. Rush et al., "Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline", NEUROPSYCH, 25(1), 2001, pp. 131-138

Abstract

Our objective was to determine if pretreatment anxiety levels were associated with preferential response to bupropion sustained release (n = 122) or sertraline (n = 126) during a 16-week randomized acute phase treatment study. Both agents had comparable antidepressant activity, and comparable anxiolytic effects using the intent-to-treat sample. Baseline anxiety levels were not related to antidepressant efficacy, and they did not differentiate responders to each agent. Time to clinically significant anxiolysis did not differentiate between treatment groups or between responders to each agent. These results contradict the commonly held, but unsubstantiated, belief that in clinically depressed anxious patients, serotonergic antidepressants are especially anxiolytic and that such patients preferentially benefit from the antidepressant or anxiolytic effects of selective serotonin reuptake inhibitors. Thus, the clinical decision to select between these two agents when treating depressed outpatients cannot rest on either levels of pretreatment anxiety or on anticipation of more rapid or more complete anxiolysis. [Neuropsychopharmacology 25:131-138, 2001] (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 21:39:24